While gene therapy for one form LCA has already been FDA-approved (LCA caused by RPE65 mutations), one must now consider the age of the subjects that need to be treated (Acland et al., 2001; Narfstrom et al., 2003). Here, RPE65 is linked to Leber congenital amaurosis.